Johnson & Johnson
JNJ-N
189 watching
Join the Discussion
Comment Now
About Johnson & Johnson (JNJ-N)
Johnson & Johnson is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company founded in 1886.
More at Wikipedia
0
0
0
0
0
Your ReactionSignal
Opinion
Expert
COMMENT
COMMENT
November 7, 2019
High opinion of the company. Will be able to work through legal troubles. One-stop shop with pharma, consumer. Good brand names that will weather the storm. Earnings powerhouse. Good dividend. Short-term bumpiness, but well managed. Yield is 2.9%.
High opinion of the company. Will be able to work through legal troubles. One-stop shop with pharma, consumer. Good brand names that will weather the storm. Earnings powerhouse. Good dividend. Short-term bumpiness, but well managed. Yield is 2.9%.
biotechnology/pharmaceutical
BUY WEAKNESS
BUY WEAKNESS
November 5, 2019
The pharma sector. Any picks? Pharma's problem is the US election cycle when candidates always bash big pharma. But these stocks are not expensive now, like JNJ which boasts 3 divisions (consumer, medical devices and pharma); and Novo Nordisk, which offers a diabetes pill and obesity pill. Buy a small position now as well as when they pull back during the election campaign, and certainly after the election. NVO increases its dividend perennially. The Dems and Republicans are equally critical of pharma.
The pharma sector. Any picks? Pharma's problem is the US election cycle when candidates always bash big pharma. But these stocks are not expensive now, like JNJ which boasts 3 divisions (consumer, medical devices and pharma); and Novo Nordisk, which offers a diabetes pill and obesity pill. Buy a small position now as well as when they pull back during the election campaign, and certainly after the election. NVO increases its dividend perennially. The Dems and Republicans are equally critical of pharma.
biotechnology/pharmaceutical
DON'T BUY
DON'T BUY
October 17, 2019
Wouldn't be a buyer at almost any price. Too much of an unknown with asbestos in talc, opioids, etc. Operationally, doing fine. But unknown legal liabilities in front of them, which often lead to a contraction of valuation.
Wouldn't be a buyer at almost any price. Too much of an unknown with asbestos in talc, opioids, etc. Operationally, doing fine. But unknown legal liabilities in front of them, which often lead to a contraction of valuation.
biotechnology/pharmaceutical
TOP PICK
TOP PICK
October 15, 2019
$170 is his model price, meaning 30% upside. Due to the asbestos lawsuit, this is now a good opportunity. Pays a good dividend. (Analysts’ price target is $148.84)
$170 is his model price, meaning 30% upside. Due to the asbestos lawsuit, this is now a good opportunity. Pays a good dividend. (Analysts’ price target is $148.84)
biotechnology/pharmaceutical
COMMENT
COMMENT
October 9, 2019
She's done very well with it. Litigation about opiates is the overhang, and just got a negative ruling on their anti-psychotic drug. Their drugs are doing well, but there are a lot of negative headlines. They may continue selling off troublesome drugs. They remain very profitable but also volatile.
She's done very well with it. Litigation about opiates is the overhang, and just got a negative ruling on their anti-psychotic drug. Their drugs are doing well, but there are a lot of negative headlines. They may continue selling off troublesome drugs. They remain very profitable but also volatile.
biotechnology/pharmaceutical
TOP PICK
TOP PICK
October 7, 2019
Heath care stocks have not been in favour. JNJ-N has been in the penalty box with the opioid lawsuits. They only had 1% of the sales in this, however. (Analysts’ price target is $148.53)
Heath care stocks have not been in favour. JNJ-N has been in the penalty box with the opioid lawsuits. They only had 1% of the sales in this, however. (Analysts’ price target is $148.53)
biotechnology/pharmaceutical
BUY WEAKNESS
BUY WEAKNESS
September 6, 2019
The talcum and now opiod crisis will continue to cause them to pay out until the regulators are satisfied. He would be a buyer on weakness.
The talcum and now opiod crisis will continue to cause them to pay out until the regulators are satisfied. He would be a buyer on weakness.
biotechnology/pharmaceutical
DON'T BUY
DON'T BUY
August 27, 2019
The talcum power and opioid issues are being worked out. If you extrapolate what could come from other states, it could become a real issue. There was knowledge on the talcum issue for years. He would stay away from this.
The talcum power and opioid issues are being worked out. If you extrapolate what could come from other states, it could become a real issue. There was knowledge on the talcum issue for years. He would stay away from this.
biotechnology/pharmaceutical
DON'T BUY
DON'T BUY
August 22, 2019
There is a ruling on Monday. This is a great reason not to buy it. Some people think you should not sell it even if you would not buy it if you held it. He would stay clear of it. There is one law suit after another.
There is a ruling on Monday. This is a great reason not to buy it. Some people think you should not sell it even if you would not buy it if you held it. He would stay clear of it. There is one law suit after another.
biotechnology/pharmaceutical
BUY
BUY
August 21, 2019
Really a healthcare conglomerate that has medtech and health devices. They also have medical and household products. They are currently trading at a lower multiple, due to the sector being under pressure from legislation. They also have the baby powder lawsuit, which shouldn't be too much of a problem, but the stock price takes a hit when news comes out.
Really a healthcare conglomerate that has medtech and health devices. They also have medical and household products. They are currently trading at a lower multiple, due to the sector being under pressure from legislation. They also have the baby powder lawsuit, which shouldn't be too much of a problem, but the stock price takes a hit when news comes out.
biotechnology/pharmaceutical
DON'T BUY
DON'T BUY
August 13, 2019
biotechnology/pharmaceutical
TOP PICK
TOP PICK
July 29, 2019
He loves the healthcare space. His model price is over $179. Yield 2.85%
He loves the healthcare space. His model price is over $179. Yield 2.85%
biotechnology/pharmaceutical
PAST TOP PICK
PAST TOP PICK
July 10, 2019
(A Top Pick Jul 10/18, Up 14%) They had a lot of issues in the last year. Their phrama division is about half of their revenues and is doing quite well. This division has the highest margins. They have increased the dividend for 56 consecutive years. She would not jump in right now; buy on a pull-back.
(A Top Pick Jul 10/18, Up 14%) They had a lot of issues in the last year. Their phrama division is about half of their revenues and is doing quite well. This division has the highest margins. They have increased the dividend for 56 consecutive years. She would not jump in right now; buy on a pull-back.
biotechnology/pharmaceutical
COMMENT
COMMENT
June 5, 2019
Lawsuit impacts? It is facing a lawsuit on talcum powder impact on babies. These type of lawsuits can be dragged out and become an uphill battle for the company. Since this does not represent a major portion of the revenues, it should not be a long term influence. The risk is the market will redetermine the correct trading multiple and that is hard to predict. He would rather trade a medical device ETF, that includes JNJ-N.
Lawsuit impacts? It is facing a lawsuit on talcum powder impact on babies. These type of lawsuits can be dragged out and become an uphill battle for the company. Since this does not represent a major portion of the revenues, it should not be a long term influence. The risk is the market will redetermine the correct trading multiple and that is hard to predict. He would rather trade a medical device ETF, that includes JNJ-N.
biotechnology/pharmaceutical
BUY WEAKNESS
BUY WEAKNESS
June 4, 2019
They are a one stop shop in the consumer staple space with good demographic support. He expects dividend growth to continue. The negative is on the political side, which might hurt the healthcare space. He would definitely buy on weakness.
They are a one stop shop in the consumer staple space with good demographic support. He expects dividend growth to continue. The negative is on the political side, which might hurt the healthcare space. He would definitely buy on weakness.
biotechnology/pharmaceutical
TOP PICK
TOP PICK
May 22, 2019
Just bought it Friday. A healthcare stock under pressure from law suites associated to its talcum products. A great company to own long term.
Yield 2.7% (Analysts’ price target is $148.47)
Just bought it Friday. A healthcare stock under pressure from law suites associated to its talcum products. A great company to own long term.
Yield 2.7% (Analysts’ price target is $148.47)
biotechnology/pharmaceutical
BUY WEAKNESS
BUY WEAKNESS
May 14, 2019
Buy on a pullback, not now. Their pharma division is doing very well with products in the pipeline and wide margins. A strong balance sheet. Their dividend is almost 3% with a long history of increasing. A diversified, global name. This is quite defensive and good to hold in a weak economy. Lawsuits remain an overhang; JNJ has likely put aside some contingency money for these suits.
Buy on a pullback, not now. Their pharma division is doing very well with products in the pipeline and wide margins. A strong balance sheet. Their dividend is almost 3% with a long history of increasing. A diversified, global name. This is quite defensive and good to hold in a weak economy. Lawsuits remain an overhang; JNJ has likely put aside some contingency money for these suits.
biotechnology/pharmaceutical
WAIT
WAIT
March 26, 2019
Always worried about large US potential lawsuits. Suffering like all the other pharma companies. Devices and consumer brands are keeping it going. Stock is not cheap. Wait for a better entry price. Lawsuits are an overhang. (Analysts’ price target is $145.00)
Always worried about large US potential lawsuits. Suffering like all the other pharma companies. Devices and consumer brands are keeping it going. Stock is not cheap. Wait for a better entry price. Lawsuits are an overhang. (Analysts’ price target is $145.00)
biotechnology/pharmaceutical
Lorne Steinberg
President & Portfolio Manager, Lorne Steinberg Wealth Management Inc
$138.570
Unknown
BUY
BUY
February 12, 2019
It's in a great space now, healthcare, given demographics and technology. The lawsuit will linger for a long time, but it's not hugely material. JNJ is a healthcare conglomrerate with consumer, medical devices and pharma divisions. It's like an ETF. A fine healthcare stock. A long-term hold if you can weather volatility surrounding the lawsuit.
It's in a great space now, healthcare, given demographics and technology. The lawsuit will linger for a long time, but it's not hugely material. JNJ is a healthcare conglomrerate with consumer, medical devices and pharma divisions. It's like an ETF. A fine healthcare stock. A long-term hold if you can weather volatility surrounding the lawsuit.
biotechnology/pharmaceutical
HOLD
HOLD
February 8, 2019
When to exit? He thinks you "go to war" with this stock. He sees 18% upside still for it. He would continue to hold it long term. He might trim some length if it makes a new high.
When to exit? He thinks you "go to war" with this stock. He sees 18% upside still for it. He would continue to hold it long term. He might trim some length if it makes a new high.
biotechnology/pharmaceutical
DON'T BUY
DON'T BUY
February 6, 2019
He likes it, but wouldn't buy it. Consumer, pharma and devices are their three divisions. Only the consumer division is a problem; it has a baby powder cancer issue which is tainting the overall brand. Another headwind is branding: brands aren't any better than generics, as consumers now realize.
He likes it, but wouldn't buy it. Consumer, pharma and devices are their three divisions. Only the consumer division is a problem; it has a baby powder cancer issue which is tainting the overall brand. Another headwind is branding: brands aren't any better than generics, as consumers now realize.
biotechnology/pharmaceutical
COMMENT
COMMENT
January 25, 2019
Trading at 15x earnings after a pullback. It's a complicated company with so many products and now has this talcum powder issue. You won't go too wrong owning this, but will this be a compounder? He doesn't know. It's probably undervalued because of the talcum-cancer scare; markets *always* overreact to bad news. Always.
Trading at 15x earnings after a pullback. It's a complicated company with so many products and now has this talcum powder issue. You won't go too wrong owning this, but will this be a compounder? He doesn't know. It's probably undervalued because of the talcum-cancer scare; markets *always* overreact to bad news. Always.
biotechnology/pharmaceutical
BUY
BUY
January 22, 2019
They just reported solid earnings, though the stock was down today a bit. Has a wide product range sold in 200 countries. Solid and diversified. They raise their dividend every year and it rise again.
They just reported solid earnings, though the stock was down today a bit. Has a wide product range sold in 200 countries. Solid and diversified. They raise their dividend every year and it rise again.
biotechnology/pharmaceutical
BUY
BUY
January 10, 2019
Would the hiccup they had with the baby powder be a problem for the company and it is safe to step in? - Still own this company. They had it for a couple of years. The company said the product is safe and they said that the evidence is in their side. It is a triple A rated company. Their pharmaceutical division is doing very well. The dividend is very attractive and with the pullback it is good to step in.
Would the hiccup they had with the baby powder be a problem for the company and it is safe to step in? - Still own this company. They had it for a couple of years. The company said the product is safe and they said that the evidence is in their side. It is a triple A rated company. Their pharmaceutical division is doing very well. The dividend is very attractive and with the pullback it is good to step in.
biotechnology/pharmaceutical
BUY WEAKNESS
BUY WEAKNESS
December 20, 2018
One of the biggest companies in the world. Pharama and consumer products. They were hit with a multi-billion dollar law suit that their baby powder has chemicals in it rather than just talc.
One of the biggest companies in the world. Pharama and consumer products. They were hit with a multi-billion dollar law suit that their baby powder has chemicals in it rather than just talc.
biotechnology/pharmaceutical
DON'T BUY
DON'T BUY
December 19, 2018
It is suffering from asbestos in their talcum powder. This issue goes back four decades. The company is doing major damage control and he is not sure how it will end up. He would stay way.
It is suffering from asbestos in their talcum powder. This issue goes back four decades. The company is doing major damage control and he is not sure how it will end up. He would stay way.
biotechnology/pharmaceutical
BUY
BUY
December 13, 2018
This is a portfolio anchor type of company. It is defensive and pays a great dividend for a US equity. If you want to make a bet on Pharma you would not use this one because there are two other businesses in there. These other two businesses give it some diversification. It is a good long term play.
This is a portfolio anchor type of company. It is defensive and pays a great dividend for a US equity. If you want to make a bet on Pharma you would not use this one because there are two other businesses in there. These other two businesses give it some diversification. It is a good long term play.
biotechnology/pharmaceutical
HOLD
HOLD
November 16, 2018
Worries about if markets do sell off. It’s had a great run up. It would have to get above levels it’s at. He’d buy because it’s still trending higher, but with the caveat to be careful with the DOW and S&P if they start to sell off.
Worries about if markets do sell off. It’s had a great run up. It would have to get above levels it’s at. He’d buy because it’s still trending higher, but with the caveat to be careful with the DOW and S&P if they start to sell off.
biotechnology/pharmaceutical
Elliott Fishman
Director of U.S. and international equity trading, Trading Services Group, Scotia Wealth
$145.990
Unknown
COMMENT
COMMENT
November 12, 2018
Avoided today's sell-off. Chart has a fantastic uptrend since 2014, though it's been oversold and overbought in periods. Current price is just below its January peak. This year it has a cup and handle pattern, which is good. It's not testing its January high. JNJ come be a defensive play, or it could go sideways or even drift down.
Avoided today's sell-off. Chart has a fantastic uptrend since 2014, though it's been oversold and overbought in periods. Current price is just below its January peak. This year it has a cup and handle pattern, which is good. It's not testing its January high. JNJ come be a defensive play, or it could go sideways or even drift down.
biotechnology/pharmaceutical
HOLD
HOLD
November 9, 2018
He is overweight in both pharmaceuticals and biotechnology. It is nearing a 52 week high. They have continuously raised the dividend. It is a defensive name. There are other names in this sector that he prefers.
He is overweight in both pharmaceuticals and biotechnology. It is nearing a 52 week high. They have continuously raised the dividend. It is a defensive name. There are other names in this sector that he prefers.
biotechnology/pharmaceutical
Rob Tetrault
Portfolio Manager and Senior Vice-President, Tetrault Wealth Advisory Group from National Bank
$145.340
No
Comments
00000
© Stockchase Inc.
1
Stock saved to your watch list successfully.View Watch List
